NCT04746196

Galectin-3 Level in Ankylosing Spondylitis Patients

Relationship Between Galectin-3 Level and Disease Activity in Ankylosing Spondylitis Patients

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 80 (actual)
• Sponsor: Recep Tayyip Erdogan University Training and Research Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Accepted

Summary

Forty-five AS patients and 35 healthy controls were enrolled in this study. Patients diagnosed with AS according to Modified New York criteria were included in the study. Clinical and laboratory measurements, duration of symptoms, age and body mass index (BMI) of AS patients were performed and compared with age and BMI matched control group.

Detailed description

Detailed histories of all participants were obtained, and systemic and rheumatologic examinations were performed. We excluded all participants who had a history of hyperlipidemia, liver, renal, hematological, familial thyroid, neoplastic, autoimmune infectious diseases and receiving anti-inflammatory drugs. We measured serum galectin-3 levels using a commercial chemiluminescent microparticle immunoassay. The Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) was used to assess disease activity in AS patients.

Conditions

• Ankylosing Spondylitis

Interventions

Type	Name	Description
OTHER	Serum galectin-3 concentration was measured.	Serum galectin-3 concentration was measured using a commercial chemiluminescent microparticle immunoassay.

Timeline

• Start date: 2017-01-01
• Primary completion: 2017-06-30
• Completion: 2017-08-30
• First posted: 2021-02-09
• Last updated: 2021-04-20